|
21 Companies |
|
32 Products |
|
32 Products |
|
31 Mechanisms of Action |
|
0 Trials |
|
632 News |
|
| «123456789101112» |
- Enrollment closed: Comparison of the New Fitting Method Cochlear Nucleus Fitting Software (NFS) With the Established Fitting Method Cochlear Nucleus Custom SoundTM Suite (CSS) (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=48, Active, not recruiting, Sponsor: Cochlear
Recruiting --> Active, not recruiting
- | Trial completion: HYBERNATUS: Evaluation of Therapeutic Hypothermia in Convulsive Status EPILEPTICUS in Adults in Intensive Care (clinicaltrials.gov) - Sep 29, 2016
P3, N=270, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial primary completion date, Monotherapy: Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures (clinicaltrials.gov) - Sep 29, 2016
P3, N=815, Completed, Sponsor: Bial - Portela C S.A.
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Sep 2016
- |||| Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Trial primary completion date, Monotherapy: Eslicarbazepine Acetate Monotherapy Long Term Study (clinicaltrials.gov) - Sep 16, 2016
P3, N=348, Active, not recruiting, Sponsor: Sunovion
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Aug 2016 --> Dec 2016
- |||| Trial completion: Pediatric Epilepsy Trial in Subjects 1-24 Months (clinicaltrials.gov) - Sep 14, 2016
P2, N=177, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2016 --> Dec 2016 No longer recruiting --> Completed
- |||| everolimus / Generic mfg.
Trial primary completion date: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Sep 12, 2016
P3, N=365, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed Trial primary completion date: Oct 2016 --> Oct 2017
- |||| levetiracetam / Generic mfg.
Trial completion: UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry) (clinicaltrials.gov) - Sep 3, 2016
P4, N=516, Completed, Sponsor: UCB Pharma
Trial primary completion date: Oct 2016 --> Oct 2017 Active, not recruiting --> Completed
- || brivaracetam / Generic mfg.
Trial completion: Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy (clinicaltrials.gov) - Aug 19, 2016
P3b, N=26, Completed, Sponsor: UCB Pharma SA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| lacosamide / Generic mfg.
Enrollment closed: Study to Investigate Lacosamide as Add-on Therapy in Subjects ?4 Years to <17 Years of Age With Partial Onset Seizures (clinicaltrials.gov) - Aug 3, 2016
P3, N=340, Active, not recruiting, Sponsor: UCB Pharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| vigabatrin / Generic mfg.
Trial completion, Enrollment change: Sabril Patient Registry (clinicaltrials.gov) - Jul 30, 2016
P=N/A, N=9423, Completed, Sponsor: Lundbeck LLC
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=15000 --> 9423
- Enrollment closed, Trial primary completion date: Copeptin in Childhood Epilepsy (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=340, Active, not recruiting, Sponsor: University Hospital, Basel, Switzerland
Enrolling by invitation --> Completed | N=15000 --> 9423 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- Trial primary completion date: People Presenting With Neurocysticercosis in North America (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=200, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Jul 2017 --> Jan 2030
- |||||| lacosamide / Generic mfg.
Enrollment open, Trial primary completion date: Study to Investigate Lacosamide as Add-on Therapy in Subjects ?4 Years to <17 Years of Age With Partial Onset Seizures (clinicaltrials.gov) - Jun 29, 2016
P3, N=340, Recruiting, Sponsor: UCB Pharma
Trial primary completion date: Jul 2017 --> Jan 2030 Active, not recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Jan 2017
- ||||| Enrollment change: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder (clinicaltrials.gov) - Jun 28, 2016
P3, N=54, Enrolling by invitation, Sponsor: INSYS Therapeutics Inc
Active, not recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Jan 2017 N=232 --> 54
- ||||| Trial initiation date, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome (clinicaltrials.gov) - Jun 24, 2016
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
N=232 --> 54 Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Dec 2016 --> Jun 2017
- ||||| Trial initiation date, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome (clinicaltrials.gov) - Jun 24, 2016
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Dec 2016 --> Jun 2017 Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Dec 2016 --> Jun 2017
- ||| Plumiaz (diazepam nasal spray) / Acorda
Enrollment closed, Enrollment change: An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray. (clinicaltrials.gov) - Jun 14, 2016
P2, N=126, Active, not recruiting, Sponsor: Acorda Therapeutics
Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=100 --> 126
- |||| brivaracetam / Generic mfg.
Trial primary completion date: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam (clinicaltrials.gov) - Jun 5, 2016
P3, N=108, Active, not recruiting, Sponsor: UCB Pharma
Recruiting --> Active, not recruiting | N=100 --> 126 Trial primary completion date: Dec 2017 --> Oct 2016
- brivaracetam / Generic mfg.
Phase classification: Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy (clinicaltrials.gov) - Jun 2, 2016
P3b, N=26, Active, not recruiting, Sponsor: UCB Pharma SA
Trial primary completion date: Dec 2017 --> Oct 2016 Phase classification: P3 --> P3b
- Trial completion, Enrollment change, Trial primary completion date: Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=185, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Phase classification: P3 --> P3b Recruiting --> Completed | N=1500 --> 185 | Trial primary completion date: Dec 2013 --> Jul 2014
- lacosamide / Generic mfg.
Trial primary completion date: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) - Jun 1, 2016
P2, N=50, Recruiting, Sponsor: UCB Pharma
Recruiting --> Completed | N=1500 --> 185 | Trial primary completion date: Dec 2013 --> Jul 2014 Trial primary completion date: Mar 2018 --> Dec 2017
- Trial completion, Enrollment change: EpiCapno: Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask (clinicaltrials.gov) - May 21, 2016
P=N/A, N=10, Completed, Sponsor: University of Aarhus
Trial primary completion date: Mar 2018 --> Dec 2017 Recruiting --> Completed | N=20 --> 10
- |||| Enrollment status: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder (clinicaltrials.gov) - May 18, 2016
P3, N=232, Enrolling by invitation, Sponsor: INSYS Therapeutics Inc
Recruiting --> Completed | N=20 --> 10 Recruiting --> Enrolling by invitation
- |||| Trial completion: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders (clinicaltrials.gov) - May 18, 2016
P1/2, N=61, Completed, Sponsor: INSYS Therapeutics Inc
Recruiting --> Enrolling by invitation Recruiting --> Completed
- ||||| lacosamide / Generic mfg.
Enrollment closed: Study to Investigate Lacosamide as Add-on Therapy in Subjects ?4 Years to <17 Years of Age With Partial Onset Seizures (clinicaltrials.gov) - May 16, 2016
P3, N=308, Active, not recruiting, Sponsor: UCB Pharma
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| lacosamide / Generic mfg., carbamazepine / Generic mfg.
Trial primary completion date, Monotherapy: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (clinicaltrials.gov) - May 10, 2016
P3, N=551, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Dec 2016
- ||||||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial completion, Trial primary completion date, Monotherapy: Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures (clinicaltrials.gov) - May 3, 2016
P3, N=815, Completed, Sponsor: Bial - Portela C S.A.
Trial primary completion date: Mar 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015
- Trial primary completion date: Comparison of the New Fitting Method Cochlear Nucleus Fitting Software (NFS) With the Established Fitting Method Cochlear Nucleus Custom SoundTM Suite (CSS) (clinicaltrials.gov) - May 3, 2016
P=N/A, N=48, Recruiting, Sponsor: Cochlear
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015 Trial primary completion date: Jun 2017 --> Jan 2018
- |||| Potiga (retigabine) / Bausch Health, GSK
Trial primary completion date: Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097 (clinicaltrials.gov) - Apr 27, 2016
P3, N=376, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2017 --> Jan 2018 Trial primary completion date: Dec 2015 --> Dec 2016
- || levetiracetam / Generic mfg.
Trial completion: An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures (clinicaltrials.gov) - Apr 27, 2016
P3, N=44, Completed, Sponsor: UCB Pharma
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Trial primary completion date: Cardiac Arrhythmias in Epilepsy: the CARELINK-study (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=50, Active, not recruiting, Sponsor: Stichting Epilepsie Instellingen Nederland
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Dec 2016
- Trial completion, Trial primary completion date: Epilepsy Impact Scale (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=51, Completed, Sponsor: Stanford University
Trial primary completion date: Jun 2016 --> Dec 2016 Enrolling by invitation --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- | lacosamide / Generic mfg.
Trial initiation date, Trial primary completion date: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) - Apr 7, 2016
P2, N=50, Recruiting, Sponsor: UCB Pharma
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Trial primary completion date: Jul 2016 --> Mar 2018 | Initiation date: Oct 2013 --> Feb 2014
- Trial primary completion date: Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients (clinicaltrials.gov) - Apr 1, 2016
P3, N=80, Recruiting, Sponsor: Sara Varea
Trial primary completion date: Jul 2016 --> Mar 2018 | Initiation date: Oct 2013 --> Feb 2014 Trial primary completion date: Feb 2016 --> Sep 2017
- Trial primary completion date: PTEpD: Preliminary Testing of a Novel Device to Detect Epileptic Seizures (clinicaltrials.gov) - Mar 22, 2016
P=N/A, N=126, Recruiting, Sponsor: University of Edinburgh
Trial primary completion date: Feb 2016 --> Sep 2017 Trial primary completion date: Feb 2016 --> Aug 2016
- Trial termination: Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit (clinicaltrials.gov) - Mar 18, 2016
P4, N=5, Terminated, Sponsor: New York University School of Medicine
Trial primary completion date: Feb 2016 --> Aug 2016 Suspended --> Terminated; Investigator is leaving the institution and has terminated the study.
- Trial initiation date: Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression. (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=200, Not yet recruiting, Sponsor: Centre for Addiction and Mental Health
Suspended --> Terminated; Investigator is leaving the institution and has terminated the study. Initiation date: Dec 2015 --> Dec 2016
- ||||||| levetiracetam / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization (clinicaltrials.gov) - Mar 8, 2016
P3, N=126, Completed, Sponsor: Ache Laboratorios Farmaceuticos S.A.
Initiation date: Dec 2015 --> Dec 2016 Not yet recruiting --> Completed | N=200 --> 126 | Initiation date: Dec 2011 --> Jan 2013 | Trial primary completion date: Jan 2013 --> Jul 2015
- Trial completion: WEPOD: Women With Epilepsy: Pregnancy Outcomes and Deliveries (clinicaltrials.gov) - Mar 8, 2016
P=N/A, N=199, Completed, Sponsor: New York University School of Medicine
Not yet recruiting --> Completed | N=200 --> 126 | Initiation date: Dec 2011 --> Jan 2013 | Trial primary completion date: Jan 2013 --> Jul 2015 Active, not recruiting --> Completed
- Trial completion, HEOR: Enhancing Physical Activity Levels in Children With Epilepsy (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=45, Completed, Sponsor: Children's Hospital of Eastern Ontario
Active, not recruiting --> Completed Active, not recruiting --> Completed
- levetiracetam / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Seizure Prophylaxis in Aneurysm Repair (clinicaltrials.gov) - Feb 29, 2016
P4, N=17, Terminated, Sponsor: Indiana University
N=266 --> 17 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Feb 2016; Lack of enrollment - since the start of the study in 2013, only 17 subjects have consented. Of those, only 8 completed the study.
- |||| Trial completion: Multicenter Trial for Adults With Partial Seizures (clinicaltrials.gov) - Feb 27, 2016
P2, N=190, Completed, Sponsor: Teva Pharmaceutical Industries
Of those, only 8 completed the study. No longer recruiting --> Completed
- Trial primary completion date: Comparison of the New Fitting Method Cochlear Nucleus Fitting Software (NFS) With the Established Fitting Method Cochlear Nucleus Custom SoundTM Suite (CSS) (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=48, Recruiting, Sponsor: Cochlear
No longer recruiting --> Completed Trial primary completion date: Dec 2016 --> Jun 2017
- Trial completion: Why Are Patients With Absence Seizures Absent? A Brain Imaging Study (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=180, Completed, Sponsor: Yale University
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Completed
- Biomarker, Trial primary completion date: Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- || Trial primary completion date: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders (clinicaltrials.gov) - Jan 17, 2016
P1/2, N=60, Recruiting, Sponsor: INSYS Therapeutics Inc
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- Trial primary completion date: Exercise Education for Adults With Seizure Disorders (clinicaltrials.gov) - Jan 17, 2016
P0, N=50, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- || Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial primary completion date: Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) (clinicaltrials.gov) - Jan 17, 2016
P=N/A, N=300, Active, not recruiting, Sponsor: Bial - Portela C S.A.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- | brivaracetam / Generic mfg.
Enrollment change: Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy (clinicaltrials.gov) - Jan 15, 2016
P3, N=26, Active, not recruiting, Sponsor: UCB Pharma SA
Trial primary completion date: Dec 2015 --> Dec 2016 N=650 --> 26
- |||||| Enrollment open, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder (clinicaltrials.gov) - Jan 5, 2016
P3, N=232, Recruiting, Sponsor: INSYS Therapeutics Inc
N=650 --> 26 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Dec 2017